Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV.

Abstract

MS patients were one of the first populations vaccinated in Iran. To date, the most used vaccine brand on Iranian MS patients is Sinopharm COVID-19 vaccine. Here is the first study on the adverse events after the first dose of Sinopharm vaccine on 583 Iranian MS patients. A Google form link was sent to MS patients through social networks, between May 1, 2021 and May 22, 2021. No serious adverse event was reported. At least one complaint (mostly transient) was reported by 350 (60%) of vaccine recipients. Constitutional symptoms (malaise, fatigue, fever, shivering, & generalized body pain) (51%) and headache (9%) were the most reported complaints. We found a relation between gender and prior infection with COVID-19 and reported symptoms (p value less than 0.05). Only five recipients (0.9%) reported MS relapse after vaccination. MS worsening was a minor incident related to fever.

• Authors: Mohammad Ali Sahraian, Fereshteh Ghadiri, Amirreza Azimi, Abdorreza Naser Moghadasi
• Journal: Vaccine (Vaccine) Vol. 39 Issue 43 Pg. 6347-6350 (10 15 2021) ISSN: 1873-2518 [Electronic] Netherlands
• PMID: 34579974 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier Ltd. All rights reserved.

Chemical References

• COVID-19 Vaccines

Topics

• COVID-19
• COVID-19 Vaccines
• Humans
• Iran (epidemiology)
• Multiple Sclerosis (epidemiology)
• SARS-CoV-2